In January 2022, Lonza Walkersville and its joint-venture partner Octane Biotech sued Miltenyi Biotec in the District of Maryland, alleging that Miltenyi’s CliniMACS Prodigy system, the automated platform used across the field to manufacture CAR-T and other engineered cell products, infringed four patents covering automated bioreactor technology.[1] Neither company makes a drug. Both make the machine that makes the drug. The dispute produced a claim construction ruling from a federal judge on terms as narrow as the word “automatically,” and the docket closed in April 2025.[2] Companies running a CliniMACS Prodigy or a Lonza Cocoon Platform in a manufacturing suite at the time the case was filed had, in most cases, no visibility into it.
That is the pattern this article documents. Composition-of-matter patents on a cell therapy get tracked in licensing diligence, in 10-K risk factors, in investor decks. The patents covering the equipment, the closed-system tubing, the automated bioreactor logic, and the cell-processing protocol a contract development and manufacturing organization (CDMO) actually uses rarely get the same scrutiny, because they do not sit in a database anyone checks by habit. DrugPatentWatch tracks patent families tied to approved and investigational products, and process and manufacturing-equipment patents belong in that picture even though they attach to a machine or a method rather than a molecule.
The Short Answer
Cell and gene therapy manufacturing runs on a small set of platforms and CDMOs, and the patents protecting that machinery and methodology are not centrally listed anywhere the way small-molecule patents appear in the FDA Orange Book. A sponsor can hold a clean freedom-to-operate opinion on its own construct and still inherit infringement exposure through the equipment or process its manufacturer uses, as Lonza and Octane allege happened with Miltenyi’s Prodigy system[1] and as Lonza itself alleged happened when Northwest Biotherapeutics’ contract manufacturer used a patented gene-expression system in 2007.[3] Separately, CDMO relationships fail for reasons that have nothing to do with patents at all: acquisition of the manufacturer, as when Thermo Fisher bought Brammer Bio for $1.7 billion in 2019,[4] geopolitical decoupling under the BIOSECURE Act,[5] and buyer consolidation, as in Novo Holdings’ $16.5 billion purchase of Catalent.[6] Any of these events can force a technology transfer to a new manufacturer, and that transfer is the moment a dormant manufacturing patent, one nobody checked at signing, becomes a live problem.
Why Cell Therapy Manufacturing Patents Are Different From Orange Book Patents
No Orange Book, No Purple Book Listing for Process Patents
Small-molecule drugs come with a public patent map. The Orange Book lists the patents a brand company believes cover the approved drug product, and generic applicants have to certify against each one before they can launch. Biologics get a thinner version of the same idea in the Purple Book, tied to reference product exclusivity. Neither database requires a company to list the patents covering how a product is manufactured. A cell therapy sponsor’s Investigational New Drug application and Biologics License Application describe the manufacturing process to the FDA in detail, but that description is not published, and it says nothing about who owns the intellectual property behind the equipment, reagents, or protocol steps used to make the product.
Process Patents Attach to Equipment and Protocols, Not Molecules
A composition-of-matter patent on a chimeric antigen receptor construct blocks a specific molecule. A manufacturing patent can block a category of activity: “automatically adjusting” a bioreactor’s temperature and pH without human input was one of the exact claim terms a federal court in Maryland construed in the Lonza-Miltenyi case.[7] That kind of claim does not name a drug. It names a way of running a process, which means it can read on any product manufactured that way, regardless of which sponsor owns the therapy.
An Original Taxonomy: Four Types of Cell Therapy Manufacturing IP Exposure
Based on the litigation and licensing patterns documented in this article, cell and gene therapy manufacturing IP exposure falls into four categories that sponsors budget for at very different rates.
Type 1: Platform and Equipment Patents
Patents covering the physical instrument used to process cells, such as the claims Lonza and Octane asserted against Miltenyi’s CliniMACS Prodigy.[1][7] A sponsor rarely owns or licenses these directly. It licenses use of the instrument from the equipment maker, and the equipment maker’s own freedom to sell that instrument is what is actually in dispute.
Type 2: Media and Reagent Formulation Patents
Patents on cell culture media, cytokine cocktails, or transduction reagents used during manufacturing. These are licensed at the reagent-supplier level and are the least visible to a sponsor’s own patent counsel, because they never appear in a sponsor’s own filings.
Type 3: CDMO Proprietary Process Patents
Patents the CDMO itself owns on its manufacturing method, separate from the equipment it uses. These usually transfer with the manufacturing agreement, but a sponsor that switches CDMOs mid-program can find its new manufacturer legally barred from replicating the old CDMO’s patented process steps.
Type 4: Upstream Academic Method Patents Licensed to the Manufacturer, Not the Sponsor
Patents originating at a university or research institute and licensed to a CDMO or platform company for manufacturing use, without a corresponding license running to every sponsor whose product passes through that manufacturer. Memorial Sloan Kettering’s exclusive license of U.S. Patent No. 7,446,190 to Juno Therapeutics is the closest documented example: the patent covered the chimeric T cell receptor technology tied to CAR-T manufacturing, and Juno’s 2017 suit against Kite Pharma argued that Kite’s manufacturing of Yescarta infringed it.[8]
The Case That Shows What Is at Stake: Lonza and Octane v. Miltenyi Biotec
What the Asserted Patents Actually Claim
Lonza Walkersville and Octane Biotech asserted four patents, referred to in the litigation as the Smith Patents after their named inventor: U.S. Patent Nos. 9,534,195, 9,701,932, 10,723,986, and 10,844,338.[7] All four derive from the same parent patent, U.S. Patent No. 8,492,140, “Automated Tissue Engineering System.”[7][9] The parent patent’s history is itself a case study in how manufacturing IP can change hands: the underlying application was originally filed in 2003, and ownership passed to Octane Biotech in 2009 through a court-appointed receiver liquidating a company called Millenium Biologix Technologies Inc.[9] The parent patent issued on July 23, 2013.[9] The Smith Patents cover a bioreactor system that automatically monitors and adjusts parameters such as temperature, pH, and dissolved gases during cell culture, without human input, to minimize contamination risk and operator error.[7]
Timeline: From the Cocoon Platform to a Claim Construction Ruling
Lonza and Octane began a joint venture in 2014 to commercialize the Cocoon Platform, an automated closed system for cell therapy manufacturing.[7] Miltenyi had launched its own automated, closed-system competitor, the CliniMACS Prodigy, the year before, in 2013.[7] Lonza sent Miltenyi a notice letter alleging infringement on May 12, 2021, nearly eight years after Miltenyi’s product launch.[10] The lawsuit followed on January 28, 2022.[11] Plaintiffs later amended the complaint twice, once to correct Miltenyi’s corporate name and once to add two more patents, U.S. Patent Nos. 11,371,018 and 11,447,745, referred to as the Shi Patents.[7] Those two additional patents were stipulated to dismissal with prejudice on May 19, 2023, narrowing the case back to the original four Smith Patents.[7] U.S. District Judge Paula Xinis held a technology tutorial and Markman hearing, then issued a claim construction opinion on December 3, 2024, largely siding with Miltenyi’s reading that “automatically” means without human input while rejecting Miltenyi’s proposed added language as redundant.[7] The docket closed on April 23, 2025.[2]
Table: The Asserted Patents at a Glance
Patent
Title/Subject
Relationship
Litigation Status
Source
US 8,492,140
Automated tissue engineering system (parent)
Not asserted; underlies the Smith Patents
Not litigated
[9]
US 9,534,195
Automated bioreactor parameter control
Smith Patent, asserted
Claim terms construed Dec. 3, 2024
[7]
US 9,701,932
Automated bioreactor parameter control
Smith Patent, asserted
Claim terms construed Dec. 3, 2024
[7]
US 10,723,986
Automated bioreactor parameter control
Smith Patent, asserted
Claim terms construed Dec. 3, 2024
[7]
US 10,844,338
Automated bioreactor parameter control
Smith Patent, asserted
Claim terms construed Dec. 3, 2024
[7]
US 11,371,018; US 11,447,745
Shi Patents, added by amendment
Asserted, then dismissed
Dismissed with prejudice May 19, 2023
[7]
Original analysis: Miltenyi launched the accused Prodigy system in 2013, the same year the foundational parent patent issued. Lonza’s notice letter did not follow until 2021, roughly eight years later, and suit was not filed until early 2022.[7][10][11] That gap is a calculated figure, not a reported one: it shows how long manufacturing-patent exposure tied to widely deployed equipment can sit unlitigated before a rights holder acts, which is exactly the span during which a sponsor using that equipment would have had no visible signal that a dispute was coming.
When the Infringement Exposure Belongs to Your CDMO, Not You
The Northwest Biotherapeutics Precedent
The Lonza-Miltenyi dispute is a fight between two manufacturing-technology companies. A different, older case shows what happens when the sponsor itself gets caught in the middle. In July 2007, Lonza Group AG sued Northwest Biotherapeutics, alleging infringement of eight patents covering recombinant DNA methods, vectors, cell lines, and host cells used in connection with Northwest’s DCVax dendritic cell vaccine products.[3] Northwest’s own 10-K/A disclosure states plainly that none of its DCVax products involved any gene modification of cells.[3] Lonza’s actual theory, once the case narrowed, was that Medarex, the contract manufacturer Northwest used to produce the PSMA antigen biomarker in DCVax-Prostate, had used Lonza’s patented gene expression system.[3] Lonza withdrew nearly all of its claims within five months, and the remaining claim over the DCVax-Prostate product was resolved when Northwest agreed only to destroy its remaining inventory of PSMA antigen that Medarex had produced, with no monetary payment and no license taken.[3]
What Happens When Your Contract Manufacturer’s Supplier Gets Sued
Northwest never touched the gene-modification technology at issue. Its supplier’s supplier, functionally, did. That is the structural risk Type 3 and Type 4 exposure create: a sponsor’s own freedom-to-operate diligence typically stops at its own construct and its own direct contracts. It does not automatically extend to auditing which patented reagents, cell lines, or expression systems a CDMO or a CDMO’s own upstream vendor used to produce a specific lot. Northwest’s outcome, a dismissal with prejudice in exchange for destroying finished inventory rather than a licensing fee, was comparatively cheap. Not every sponsor caught in that position will get the same terms.
Juno v. Kite: A Reminder That “Manufacturing” and “Composition” Patents Can Blur
The $1.2 Billion Verdict That Vanished
In September 2017, Juno Therapeutics sued Kite Pharma for infringement of U.S. Patent No. 7,446,190, “Nucleic Acids Encoding Chimeric T Cell Receptors,” which Juno exclusively licensed from Memorial Sloan Kettering Cancer Center.[8] The patent covered methods for modifying T cells with chimeric antigen receptors targeting the CD19 surface antigen, the same target used by Kite’s Yescarta, approved by the FDA in 2017, and by Juno’s own Breyanzi, which launched in 2021.[8] Juno’s complaint characterized Kite’s alleged infringement as occurring through the manufacturing process for Yescarta.[8] A jury found for Juno, and the district court entered judgment of $1,200,322,551.50.[12] On August 26, 2021, the Federal Circuit reversed, holding that no reasonable jury could find the patent’s written description adequate to support claims broad enough to cover “any scFv for binding any target,” wiping out the judgment entirely.[12][13]
Why a Written-Description Loss Still Matters for Manufacturing Claims
The ‘190 patent had already survived one validity challenge: Kite lost an earlier inter partes review at the Patent Trial and Appeal Board, which found that prior art actually taught away from the claimed CD28-based construct rather than toward it.[14] The eventual reversal turned not on novelty but on whether the patent’s written description supported the full breadth of what Juno tried to claim.[12][13] For manufacturing patents specifically, that distinction matters, because process claims, like the “automatically adjusting” language at issue in the Lonza-Miltenyi case, invite the same kind of breadth question: a claim drafted to cover an entire category of automated behavior is vulnerable to the same written-description attack that ultimately erased a $1.2 billion award.
Why CDMO Contracts Fall Through: Three Documented Failure Modes
Failure Mode One: The CDMO Gets Acquired
bluebird bio built its manufacturing strategy in the late 2010s around external partners: Brammer Bio in Cambridge, Massachusetts; Novasep in Gosselies, Belgium; MilliporeSigma’s SAFC subsidiary in Carlsbad, California; and separate drug-product agreements with Lonza Houston and apceth Biopharma in Munich.[15] In March 2019, in the same week bluebird celebrated the opening of its own wholly owned lentiviral vector plant in Durham, North Carolina, Thermo Fisher Scientific announced it was acquiring Brammer Bio for $1.7 billion, a deal driven principally by Brammer’s viral-vector manufacturing expertise.[4] Brammer had itself just announced a three-year, $200 million investment program to add more than 30 manufacturing suites, including a renovation of a Lexington, Massachusetts facility as a second commercial site alongside its original Alachua, Florida plant.[16] None of that changes a sponsor’s contract terms automatically, but it does change who is on the other end of a multi-year manufacturing agreement, what that new owner’s capacity-allocation priorities are, and whether the acquiring company’s own patent portfolio now overlaps with the process the sponsor is relying on.
Failure Mode Two: Geopolitical Decoupling
The BIOSECURE Act illustrates a failure mode with no patent dispute involved at all: a CDMO relationship can become legally unworkable through legislation. The bill was introduced in January 2024 by Representatives Raja Krishnamoorthi and Mike Gallagher, naming WuXi AppTec, WuXi Biologics, BGI Group, MGI, and Complete Genomics as “biotechnology companies of concern.”[5] A May 2024 House committee draft proposed a January 1, 2032 deadline for existing contracts to wind down, following an industry survey in which 79% of 124 surveyed biopharma companies reported at least one contract or product supported by a Chinese CDMO and warned that switching away could take as long as eight years.[5]
“Right after an industry survey suggested that switching away from Chinese CDMOs could take biopharma companies up to eight years, lawmakers have adjusted the BIOSECURE Act.”[5]
The version that was ultimately folded into a national defense bill and signed into law in December 2025 took a different shape: rather than naming the WuXi entities directly, it relies on a pre-existing Department of Defense list of companies of concern that includes BGI Group and MGI Tech but, notably, omits WuXi AppTec and WuXi Biologics on the reporting available.[17][18] Enforcement is not expected before late 2028.[18] WuXi AppTec had already begun repositioning ahead of the law regardless: in January 2025, it agreed to sell its Advanced Therapies Unit, five cell and gene therapy manufacturing and testing facilities in the United States and United Kingdom, including a late-phase and commercial viral manufacturing site in Philadelphia, to the investment firm Altaris.[19]
What Changed Between the 2024 Draft and the Law That Passed
This is a case where source freshness matters more than usual. The 2032 grandfather deadline and the explicit naming of the WuXi entities were features of a 2024 House draft that did not become law in that form.[5] The version actually signed in December 2025 uses a different targeting mechanism and, on the reporting available, does not name the WuXi companies.[17] A sponsor relying on outdated coverage of an earlier draft would be planning around a deadline and a target list the enacted law does not contain.
Failure Mode Three: Capacity Reallocation After a Buyout
Novo Holdings announced its acquisition of Catalent in February 2024 at a $16.5 billion enterprise value, a deal driven substantially by the need to secure fill-finish capacity for Novo Nordisk’s GLP-1 franchise; roughly $11 billion of that value was allocated to three Catalent fill-finish sites being folded directly into Novo Nordisk’s own production network.[20] Catalent’s customer base at the time included partnerships with Novartis, Sarepta, and Eli Lilly.[20] In October 2024, twelve consumer and labor organizations wrote to the Federal Trade Commission arguing the combined firm would have “the incentive and ability to prioritize its own production needs and to pick and choose which rival gene therapies would be allocated manufacturing capacity at current Catalent facilities.”[21] The European Commission granted unconditional approval in December 2024, concluding customers had sufficient alternative CDMOs available, and the FTC allowed the deal to proceed without challenge; it closed on December 18, 2024.[20][22][6]
A CDMO’s Own Filings Flag the Risk
Catalent’s own securities filings are worth reading directly on this point. Its fiscal 2024 earnings release lists, among its enumerated risk factors, exposure to “offerings and customers’ products that may infringe on the intellectual property rights of third parties.”[23] That is the CDMO itself, in a document filed with the Securities and Exchange Commission, identifying manufacturing-related IP infringement as a named risk to its own business, not a hypothetical raised only by outside critics.
What Happens When You Try to Switch: The Technology Transfer Problem
Comparability Data, Not Just a New Supplier Agreement
Switching a cell therapy CDMO is not a matter of terminating one supply agreement and signing another. A new manufacturer has to demonstrate comparability of the resulting product to the FDA, and if the new facility cannot replicate the prior manufacturer’s specific process steps because those steps are patented, the sponsor faces a choice between licensing the original process, at whatever price the patent holder sets once it knows the sponsor has no alternative, or redeveloping a materially different process and generating new comparability data from scratch.
How Long a Real Switch Takes
The BIOSECURE-driven wave of CDMO transitions gives a documented range for how long this actually takes in practice. The BIO survey cited above put the upper bound at roughly eight years for companies fully dependent on a Chinese CDMO.[5] Separate industry analysis of the same wave describes technology transfers adding an estimated twelve to twenty-four months to development timelines even for companies not starting from zero, alongside cost increases industry analysts put in the range of 30% to 50% tied to the premium Western CDMOs can charge amid constrained capacity.[24]
How the Technology Transfer Clock Actually Starts
The clock does not start when a sponsor decides to switch. It starts when the sponsor discovers it has to, which in the case of an acquisition, a legislative deadline, or a triggered patent dispute is rarely a date the sponsor controls.
Original Analysis: Mapping Patent Exposure Against CDMO Concentration
Methodology
This section applies simple counting and gap analysis to the publicly documented cases above; it does not draw on any proprietary dataset. Dates and figures are taken from the court filings, SEC filings, and trade press coverage cited throughout this article. Where a range appears in source material, such as the cost-increase or delay figures above, the range is reported as given rather than reduced to a single derived number. Calculated figures, such as the gap between product launch and litigation in the Lonza-Miltenyi matter, are labeled as calculations rather than presented as independently reported statistics.
What the Data Shows
Three documented failure modes, an acquisition of the manufacturer, legislative decoupling, and consolidation among CDMO owners, all landed within roughly a six-year window in the cases collected here: Brammer Bio’s sale in 2019, the BIOSECURE Act’s introduction in 2024 and enactment in 2025, and the Novo Holdings-Catalent deal closing in 2024.[4][5][20] None of these three events involved a patent claim. All three nonetheless create the exact condition, an involuntary manufacturer change, under which a sponsor is most likely to discover a Type 1 through Type 4 manufacturing patent exposure it did not previously know existed, because a forced technology transfer is what makes a sponsor’s team examine a new manufacturer’s equipment and process claims for the first time.
Why bluebird bio Built Its Own Plant Instead of Relying Only on Contracts
The Durham Facility Timeline
bluebird bio purchased a partially completed 125,000-square-foot facility in Durham, North Carolina in November 2017 for $11.5 million.[15][25] The company’s own 10-K describes an approximately $80 million buildout investment on top of that purchase price, with commercial production originally targeted for 2021.[15] The plant officially opened in March 2019 with roughly 50 employees on site, a number the company expected to grow to about 70 by the end of that year.[26][27] Even after opening its own facility, bluebird retained multi-year agreements with Novasep, MilliporeSigma’s SAFC subsidiary, Lonza Houston, and apceth Biopharma; the Durham plant supplemented rather than replaced its external network.[15]
What In-Sourcing Actually Solves, and What It Does Not
Owning a manufacturing facility removes the risk that a CDMO gets acquired out from under a sponsor, as happened to Brammer Bio’s other customers when Thermo Fisher bought it the same week bluebird’s Durham plant opened.[4] It does not remove Type 1 or Type 2 exposure. A wholly owned facility still runs on licensed equipment, licensed media, and, in some cases, licensed process steps from an outside platform provider. In-sourcing shifts the failure mode from “your manufacturer got acquired or sued” to “your own facility still depends on someone else’s patented equipment,” which is a smaller category of risk but not zero.
Who Is Exposed: A Risk Framework for Sponsors
Clinical-Stage Companies With a Single CDMO
A clinical-stage sponsor using one CDMO for both process development and manufacturing has the least leverage and the least visibility into what platform patents that CDMO’s equipment might carry, since process development agreements rarely include a right to audit the manufacturer’s own IP licenses.
A commercial-stage sponsor already moving a product between manufacturers, whether for capacity reasons, cost reasons, or a BIOSECURE-driven exit from a Chinese CDMO, is the group most likely to encounter Type 3 exposure directly, because a technology transfer requires explicitly documenting the process steps being moved, which is exactly when a receiving manufacturer’s own patent counsel is most likely to flag a conflict.
Academic and Point-of-Care Manufacturers
Academic centers and point-of-care manufacturing programs that use closed-system platforms like the CliniMACS Prodigy for investigator-initiated trials are downstream of the Lonza-Miltenyi dispute in a different way: their freedom-to-operate position depends entirely on the platform maker’s own litigation outcome, a variable entirely outside their control.[1]
A Practical Red-Flag Checklist
Based on the documented cases above, three questions are reasonable to ask before signing or renewing a CDMO agreement: does the agreement identify which party bears liability if the manufacturing equipment itself is found to infringe a third party’s patent; does the agreement specify what happens to process-transfer rights if the CDMO is acquired; and has the sponsor’s own counsel checked whether the specific equipment platform named in the agreement is currently in litigation.
What This Means for Freedom to Operate in Cell and Gene Therapy
FTO Analysis Has to Include the Manufacturer’s Equipment, Not Just the Drug
A freedom-to-operate opinion scoped only to a sponsor’s own composition-of-matter and method-of-treatment claims will not surface Type 1 or Type 3 exposure, because the equipment and process patents in question are owned by someone other than the sponsor and do not name the sponsor’s drug anywhere in their claims or specification.[7]
Because manufacturing and equipment patents for cell and gene therapy are not centrally listed the way Orange Book patents are, surfacing them requires searching patent assignees, equipment makers and CDMOs directly, rather than searching only by drug name. DrugPatentWatch’s patent-tracking tools are built around that kind of assignee- and family-level search, which is useful context for this kind of exposure even though no patent database, including DrugPatentWatch, substitutes for a licensed patent attorney’s freedom-to-operate opinion on a specific manufacturing process.
What Happens Next: Scenario Analysis
Scenario One: BIOSECURE Enforcement Accelerates
If enforcement of the enacted BIOSECURE provisions moves earlier than the late-2028 estimate reported by legal advisers, the wave of forced CDMO transitions already underway across the biologics and cell and gene therapy sector would compress into a shorter window, increasing the odds that sponsors discover manufacturing-patent conflicts under time pressure rather than during ordinary diligence.[18]
Assumptions Behind This Scenario
This scenario assumes no further legislative amendment narrows or delays the current provisions, and it assumes the late-2028 enforcement estimate holds; both are stated as assumptions, not predictions of what will occur.
Scenario Two: More Platform-Patent Suits Follow Lonza v. Miltenyi
With the core Lonza-Miltenyi claim construction now resolved, other closed-system and automated bioreactor makers competing in the same space, including newer entrants building fully automated point-of-care manufacturing platforms, have a clearer picture of how a federal court will read terms like “automatically” and “optimal conditions.”[7] That clarity can cut either way: it may discourage further suits by clarifying the boundaries of the Smith Patents, or it may embolden other patent holders in the space who now have a claim-construction roadmap to follow.
Scenario Three: Consolidation Continues and Redundancy Shrinks
Each CDMO acquisition documented in this article, Brammer Bio into Thermo Fisher, Catalent into Novo Holdings, and WuXi’s Advanced Therapies Unit into Altaris, reduces the number of independently owned manufacturing options a sponsor can move to if a dispute or a forced exit arises.[4][20][19] Fewer independent CDMOs means less negotiating leverage for any sponsor caught needing to switch on short notice.
Assumptions Behind This Scenario
This scenario assumes the acquisitions documented here are representative of an ongoing trend rather than a closed chapter, which is consistent with, but not proven by, the three data points collected in this article.
Key Takeaways
Lonza Walkersville and Octane Biotech sued Miltenyi Biotec in January 2022 over four patents covering automated cell therapy manufacturing equipment; the case reached a claim construction ruling in December 2024 and closed in April 2025.[1][2][7][11]
The foundational patent behind that dispute, U.S. 8,492,140, issued in 2013 and traces its ownership back through the 2009 court-appointed receivership of a company called Millenium Biologix Technologies Inc.[9]
Lonza Group separately sued Northwest Biotherapeutics in 2007 over gene-expression patents its contract manufacturer, Medarex, allegedly used, showing sponsors can inherit manufacturing IP exposure from a supplier’s own supplier.[3]
Juno Therapeutics won a $1,200,322,551.50 jury verdict against Kite Pharma over a CAR-T patent tied to manufacturing in 2019, and the Federal Circuit reversed it entirely in August 2021 for lack of written description.[12][13]
Brammer Bio, one of bluebird bio’s lentiviral vector manufacturing partners, was acquired by Thermo Fisher for $1.7 billion in March 2019, the same week bluebird opened its own $11.5 million, 125,000-square-foot Durham, North Carolina facility.[4][15]
The BIOSECURE Act, signed into law in December 2025 as part of a defense authorization bill, relies on a Department of Defense list that includes BGI Group and MGI Tech but, per available reporting, does not name WuXi AppTec or WuXi Biologics, a shift from the explicit naming used in a 2024 House draft.[5][17]
A BIO industry survey found 79% of 124 surveyed biopharma companies had at least one contract with a China-based CDMO, and warned switching away could take up to eight years.[5]
Novo Holdings closed its $16.5 billion acquisition of Catalent in December 2024 after consumer and labor groups warned the FTC the deal could let the combined company prioritize its own manufacturing needs over rival gene therapy programs.[6][21]
Catalent’s own SEC filings list customer products that may infringe third-party intellectual property rights as a named business risk.[23]
FAQ
What is a cell therapy manufacturing patent? It is a patent covering the equipment, reagents, or process steps used to produce a cell or gene therapy, as opposed to a patent covering the therapeutic cell product itself. The Lonza-Octane patents asserted against Miltenyi’s CliniMACS Prodigy are an example: they cover automated bioreactor parameter control, not any specific drug.[7]
Are manufacturing process patents listed in the FDA Orange Book or Purple Book? No. Both databases are built around approved drug products and their exclusivity, not around the equipment or process used to manufacture them, so a sponsor has to search separately, typically by equipment maker or CDMO name, to find relevant manufacturing patents.
What happened in the Lonza and Octane v. Miltenyi Biotec case? Lonza Walkersville and Octane Biotech sued Miltenyi in January 2022, alleging its CliniMACS Prodigy system infringed four patents covering automated cell culture bioreactors. A federal judge issued a claim construction ruling in December 2024, and the case closed in April 2025.[1][2][7]
Why did Juno’s $1.2 billion verdict against Kite Pharma get reversed? The Federal Circuit found in August 2021 that the asserted patent’s written description did not support claims broad enough to cover the full range of antibody fragments Juno tried to claim, a defect independent of whether the underlying invention was novel.[12][13]
Can a sponsor be sued for patent infringement caused by its own contract manufacturer? Yes. Lonza Group’s 2007 suit against Northwest Biotherapeutics targeted Northwest even though the alleged infringing activity, use of a patented gene expression system, was actually performed by Northwest’s contract manufacturer, Medarex.[3]
What is the BIOSECURE Act and how does it affect cell therapy manufacturing? It is US legislation restricting federal-facing biopharma work with named “biotechnology companies of concern.” As enacted in December 2025, it relies on a Department of Defense list that includes BGI Group and MGI Tech; reporting indicates the WuXi entities were not named in the final version, a change from earlier 2024 drafts.[5][17] Enforcement is not expected before late 2028.[18]
Why did bluebird bio build its own manufacturing plant instead of relying only on CDMOs? bluebird purchased a Durham, North Carolina facility in 2017 to add owned lentiviral vector capacity alongside its external manufacturing agreements. The value of that decision became visible two years later, when one of its external partners, Brammer Bio, was acquired by Thermo Fisher the same week bluebird’s own plant opened.[4][15]
How long does it actually take to switch cell therapy CDMOs? Industry survey data collected around BIOSECURE-driven transitions put the upper bound at roughly eight years for companies fully dependent on a single foreign CDMO, with even partial transfers commonly estimated to add twelve to twenty-four months to development timelines.[5][24]
Why did Novo Holdings’ acquisition of Catalent raise concerns for gene therapy companies? Consumer and labor groups warned the FTC in October 2024 that the combined company could prioritize its own manufacturing needs, since Catalent’s customer base included partnerships with companies like Novartis, Sarepta, and Eli Lilly whose programs depend on shared Catalent capacity.[21][20]
How can a company check for manufacturing-related patent risk before signing a CDMO contract? Search patents by the equipment maker’s or CDMO’s name directly, since manufacturing and platform patents are not listed under the drug’s name in any FDA database, and confirm with counsel whether the specific instrument platform named in the agreement is currently in litigation.
References
Complaint analysis, Lonza Walkersville Inc. v. Miltenyi Biotec North America Inc., No. 8:22-cv-00220 (D. Md.). Ex Parte AI Lab. https://ai-lab.exparte.com/case/dct/mdd/8:22-cv-00220/doc/analysis/22
Lonza Walkersville, Inc. et al. v. Miltenyi Biotec North America, Inc., No. 8:22-cv-00220 (D. Md.), docket summary. RPX Insight. https://insight.rpxcorp.com/litigation/mddce-506456-lonza-walkersville-v-miltenyi-biotec-north-america
Northwest Biotherapeutics, Inc. (2011). Form 10-K/A, FY2009. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0001072379/000114420411004033/v208904_10ka.htm
Chemical & Engineering News. (2019, March 25). Thermo Fisher buys into gene therapy with $1.7 billion deal. https://cen.acs.org/business/outsourcing/Thermo-Fisher-buys-gene-therapy/97/web/2019/03
Fierce Pharma. (2024, May 10). House’s updated biosecurity bill sets 2032 decoupling deadline for industry’s work with WuXi AppTec, WuXi Biologics. https://www.fiercepharma.com/pharma/houses-updated-biosecurity-bill-sets-decoupling-deadline-chinese-cdmo-end-2031
Catalent, Inc. (2024, December 18). Form 8-K, Exhibit 99.1: Novo Holdings Completes Acquisition of Catalent. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1596783/000119312524280922/d902883dex991.htm
Lonza Walkersville, Inc. et al. v. Miltenyi Biotec North America, Inc., No. 8:2022cv00220, Document 89 (D. Md. Dec. 3, 2024) (Memorandum Opinion). Justia. https://law.justia.com/cases/federal/district-courts/maryland/mddce/8:2022cv00220/506456/89/
pharmaphorum. (2021, August 27). Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T case. https://pharmaphorum.com/news/appeals-court-reverses-1-2bn-judgment-against-gilead-in-bms-car-t-case
Google Patents. US8492140B2, Automated tissue engineering system. https://patents.google.com/patent/US8492140B2/da
Complaint analysis, Lonza Walkersville Inc. v. Miltenyi Biotec North America Inc. (pre-suit notice letter details). RPX Insight litigation document. https://insight.rpxcorp.com/litigation_documents/14933936
Dockets Justia. Lonza Walkersville, Inc. et al. v. Miltenyi Biotec North America, Inc., 8:2022cv00220. https://dockets.justia.com/docket/maryland/mddce/8:2022cv00220/506456
Juno Therapeutics, Inc. v. Kite Pharma, Inc., No. 20-1758 (Fed. Cir. Aug. 26, 2021) (opinion). U.S. Court of Appeals for the Federal Circuit. https://www.cafc.uscourts.gov/opinions-orders/20-1758.opinion.8-26-2021_1825257.pdf
IPWatchdog. (2021, August 26). CAFC Reverses Massive Jury Verdict for Juno and Sloan Kettering. https://www.ipwatchdog.com/2021/08/26/cafc-reverses-massive-jury-verdict-juno-sloan-kettering/id=137109/
Markman Advisors. (2018, May 30). Can Kite Pharma reverse its IPR loss challenging Juno’s CAR-T patent? https://www.markmanadvisors.com/blog/2018/5/30/can-kite-pharma-reverse-its-ipr-loss-challening-junos-car-t-patent
bluebird bio, Inc. (2019). Form 10-K, FY2018. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1293971/000156459019003694/blue-10k_20181231.htm
Chemical & Engineering News. (2019, March 25). Thermo Fisher buys into gene therapy with $1.7 billion deal [Brammer investment program detail]. https://cen.acs.org/business/outsourcing/Thermo-Fisher-buys-gene-therapy/97/web/2019/03
Fierce Pharma. (2025, December 9). Biosecure Act slips into key US defense bill, teeing up potential China biopharma constraints in ’26. https://www.fiercepharma.com/pharma/biosecure-legislation-makes-way-key-us-defense-bill-teeing-potential-china-biopharma
Vision Life Sciences. (2026, February 16). BIOSECURE Act: Pharmaceutical Outsourcing & Supply Chain Impact. https://visionlifesciences.com/insights/biosecure-act-pharma-impact-2026
BioProcess Insider. (2025, January 6). WuXi AppTec selling CGT unit as BIOSECURE continues to play out. https://www.bioprocessintl.com/deal-making/wuxi-selling-cell-therapy-unit-as-biosecure-continues-to-play-out
BioProcess Insider. (2024, December 16). Novo Catalent deal clears regulatory hurdles. https://www.bioprocessintl.com/regulations/novo-catalent-deal-clears-regulatory-hurdles
BioProcess Insider. (2024, October 21). Letter from consumer advocacy and union groups urges FTC to block Novo’s $16.5bn Catalent purchase. https://www.bioprocessintl.com/regulations/letter-urges-ftc-to-block-novo-s-16-5bn-catalent-purchase
BioPharma Dive. (2024, December 16). Novo Holdings’ purchase of Catalent set to close after regulators’ green light. https://www.biopharmadive.com/news/novo-holdings-catalent-deal-ftc-regulatory-clearance/735599/
Catalent, Inc. (2024). Form 8-K, Earnings Release Exhibit 99.1, FY2024 risk factors. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1596783/000159678324000082/earningsreleaseex991-fy24x.htm
BioMed Nexus. (2026, March 17). Biosecure Act: The 2026 Playbook, Supply Chain Decoupling Roadmap. https://biomednexus.com/biosecure-act-the-2026-playbook-supply-chain-decoupling-roadmap/
Genetic Engineering & Biotechnology News. bluebird bio Acquires Durham, NC, Manufacturing Site for Lentiviral Vector Production. https://www.genengnews.com/topics/genome-editing/bluebird-bio-acquires-durham-nc-manufacturing-site-for-lentiviral-vector-production/
bluebird bio, Inc. (2019, March 25). bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina [Press release]. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-opens-state-art-gene-and-cell-therapy-manufacturing
Fierce Pharma. (2019, August 13). Bluebird opens manufacturing facility as it moves gene therapies forward. https://www.fiercepharma.com/manufacturing/bluebird-completes-cell-and-gene-therapy-manufacturing-facility
